GEA
ACRS icon

Glen Eagle Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Glen Eagle Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$219 – 821
2019
Q2 		$219 Hold
100
– – ﹤0.01% 786
2019
Q1 		$599 Hold
100
– – ﹤0.01% 718
2018
Q4 		$739 Hold
100
– – ﹤0.01% 692
2018
Q3 		$1.45K Hold
100
– – ﹤0.01% 652
2018
Q2 		$2K Hold
100
– – ﹤0.01% 612
2018
Q1 		$1.75K Hold
100
– – ﹤0.01% 602
2017
Q4 		$2.47K Buy
+100
New +$2.44K ﹤0.01% 561

Other funds holding ACRS

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glen Eagle Advisors's ACRS Position: Q3 2019 in Review

Glen Eagle Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2019, closing a stake of 100 shares — an estimated $219 sold.

Glen Eagle Advisors first reported a position in ACRS in Q4 2017 and held it in 7 quarters. The position peaked at $2.47K in Q4 2017. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2019.

  • Glen Eagle Advisors reported no remaining Aclaris Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Glen Eagle Advisors sold 100 Aclaris Therapeutics shares in Q3 2019, an estimated $219.
  • Glen Eagle Advisors first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 7 quarters.
  • Glen Eagle Advisors's Aclaris Therapeutics position peaked at $2.47K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2019.

Based on Glen Eagle Advisors's 13F filing for Q3 2019, filed 13 Aug 2024.